Episode: 32 - SCOPE Europe 2024, AI, New Cancer Treatments, More

The Scope of Things

In this episode of the Scope of Things, host Deborah Borfitz shares the latest news on a drug repurposing AI model now being tested in rare disease clinical trials, a new way forward for triple-negative breast cancer, Jill Pellegrino’s transition from CVS to AutoCruitment, incorporating placental pathology into perspective clinical trials, making ethical oversight of clinical trials more “fit-for-purpose,” and publication bias with industry sponsored studies for psychiatric drugs. We also have Allison Proffitt, editorial director of Clinical Research News, interviewing speakers at SCOPE Europe 2024 on how AI is being used for clinical trials, their pick for the 2024 rising star in the clinical research ecosystem, and the most hotly-debated topics in trial planning and execution.
SHOW NOTES

News Roundup

AI for drug repurposing

• Study in Nature Medicine

Window trial for new breast cancer approach

• Study in Science Advances
• Article in Bio-IT World

Prescreening regimen of AutoCruitment

• Article in Clinical Research News
• Episode 12 guest appearance on podcast

Trials needing placental pathology

• Opinion piece in Trends in Molecular Medicine

Fit-for-purpose ethical oversight

• Special communication in JAMA

“Sponsorship effect” on psychiatric drug trials

• Study in Journal of Political Economy

Guests
Nicole Stansbury, Head of Global Clinical Operations at Premier Research
Farrell Healion, Head of Emerging Technologies at AstraZeneca
Jonathan Crowther, Head of Predictive Analytics, PRD (OARS), Pfizer

The Scope of Things podcast explores clinical research and its possibilities, promise, and pitfalls. Clinical Research News senior writer, Deborah Borfitz, welcomes guests who are visionaries closest to the topics, but who can still see past their piece of the puzzle. Focusing on game-changing trends and out-of-the-box operational approaches in the clinical research field, the Scope of Things podcast is your no-nonsense, insider’s look at clinical research today.